CN101111512B - 生长素释放肽受体的大环调节剂 - Google Patents
生长素释放肽受体的大环调节剂 Download PDFInfo
- Publication number
- CN101111512B CN101111512B CN2005800280726A CN200580028072A CN101111512B CN 101111512 B CN101111512 B CN 101111512B CN 2005800280726 A CN2005800280726 A CN 2005800280726A CN 200580028072 A CN200580028072 A CN 200580028072A CN 101111512 B CN101111512 B CN 101111512B
- Authority
- CN
- China
- Prior art keywords
- conditioning agent
- nnc
- application
- compound
- ghs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(CNC(C1CC1)C([N+](C)C*(NC1Cc(cc2)ccc2F)=O)=O)Oc2cc(Cl)ccc2CCCNC1=O Chemical compound CC(CNC(C1CC1)C([N+](C)C*(NC1Cc(cc2)ccc2F)=O)=O)Oc2cc(Cl)ccc2CCCNC1=O 0.000 description 18
- HQBQTVRYFJIAEW-MBIRJQTMSA-N CCC(C)[C@@H](C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1F)C(NCCC1)=O)=O)=O)NC[C@@H](C)Oc2c1ccc(F)c2 Chemical compound CCC(C)[C@@H](C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1F)C(NCCC1)=O)=O)=O)NC[C@@H](C)Oc2c1ccc(F)c2 HQBQTVRYFJIAEW-MBIRJQTMSA-N 0.000 description 2
- VBBHVZVIKKAJEG-UFKXBGGNSA-N C[C@H](C(N[C@H](Cc(cc1)ccc1Cl)C(NCCCc(ccc(Cl)c1)c1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O Chemical compound C[C@H](C(N[C@H](Cc(cc1)ccc1Cl)C(NCCCc(ccc(Cl)c1)c1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O VBBHVZVIKKAJEG-UFKXBGGNSA-N 0.000 description 2
- AXCLUVRLSOPFIA-FTKLQTQGSA-N C[C@H](C(N[C@H](Cc(cc1)ccc1Cl)C(NCCCc(cccc1CC2)c1OC2CN[C@H]1C2CC2)=O)=O)N(C)C1=O Chemical compound C[C@H](C(N[C@H](Cc(cc1)ccc1Cl)C(NCCCc(cccc1CC2)c1OC2CN[C@H]1C2CC2)=O)=O)N(C)C1=O AXCLUVRLSOPFIA-FTKLQTQGSA-N 0.000 description 2
- KUBFSPDMDRCBJF-UFKXBGGNSA-N C[C@H](C(N[C@H](Cc(ccc(Cl)c1)c1Cl)C(NCCCc1ccccc1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O Chemical compound C[C@H](C(N[C@H](Cc(ccc(Cl)c1)c1Cl)C(NCCCc1ccccc1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O KUBFSPDMDRCBJF-UFKXBGGNSA-N 0.000 description 2
- UMRFQLWVRFCHER-OXTYCOSGSA-N C[C@H](C(N[C@H](Cc1ccc(C(F)(F)F)cc1)C(NCCCc(cccc1)c1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O Chemical compound C[C@H](C(N[C@H](Cc1ccc(C(F)(F)F)cc1)C(NCCCc(cccc1)c1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O UMRFQLWVRFCHER-OXTYCOSGSA-N 0.000 description 2
- ARLDXWFDMIMAAS-ABNZCKJZSA-N C[C@H](CN[C@@H](C1CC1)C(N(C)[C@H](C)C(N[C@@H]1Cc(cc2)ccc2Cl)=O)=O)Oc2ccccc2CCCNC1=O Chemical compound C[C@H](CN[C@@H](C1CC1)C(N(C)[C@H](C)C(N[C@@H]1Cc(cc2)ccc2Cl)=O)=O)Oc2ccccc2CCCNC1=O ARLDXWFDMIMAAS-ABNZCKJZSA-N 0.000 description 2
- WGYPAJVJMXQXTR-ABNZCKJZSA-N C[C@H](CN[C@@H](C1CC1)C(N(C)[C@H](C)C(N[C@@H]1Cc(cc2)ccc2F)=O)=O)Oc2ccccc2CCCNC1=O Chemical compound C[C@H](CN[C@@H](C1CC1)C(N(C)[C@H](C)C(N[C@@H]1Cc(cc2)ccc2F)=O)=O)Oc2ccccc2CCCNC1=O WGYPAJVJMXQXTR-ABNZCKJZSA-N 0.000 description 2
- XUUGZNCJFYDZBV-IFGWQFMBSA-N C[C@H](CN[C@@H](C1CC1)C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1Cl)C(NCCC1)=O)=O)=O)Oc2c1ccc(Cl)c2 Chemical compound C[C@H](CN[C@@H](C1CC1)C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1Cl)C(NCCC1)=O)=O)=O)Oc2c1ccc(Cl)c2 XUUGZNCJFYDZBV-IFGWQFMBSA-N 0.000 description 2
- DGUAMTZAAGPLAH-MLYOZINFSA-N O=C(CCCCNC(C1(CCCC1)NCCOc1ccccc1/C=C/CN1)=O)N[C@@H](Cc2cc(Cl)ccc2)C1=O Chemical compound O=C(CCCCNC(C1(CCCC1)NCCOc1ccccc1/C=C/CN1)=O)N[C@@H](Cc2cc(Cl)ccc2)C1=O DGUAMTZAAGPLAH-MLYOZINFSA-N 0.000 description 2
- IKLNOINQWYDQGM-UHFFFAOYSA-N C1CC[IH]CC1 Chemical compound C1CC[IH]CC1 IKLNOINQWYDQGM-UHFFFAOYSA-N 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N C=Cc1ccccc1 Chemical compound C=Cc1ccccc1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- QIELQIBVEOZCNY-YVSOEDRESA-N CC(C)=C[C@@H](C(NCCCCC(N[C@H]1Cc2cc(Cl)ccc2)=O)=O)NCCOc(cccc2)c2/C=C/CNC1=O Chemical compound CC(C)=C[C@@H](C(NCCCCC(N[C@H]1Cc2cc(Cl)ccc2)=O)=O)NCCOc(cccc2)c2/C=C/CNC1=O QIELQIBVEOZCNY-YVSOEDRESA-N 0.000 description 1
- LSCPFGPGTDVAOJ-IMLLDKLASA-N CC(C)CC(C(NCCCCC(N[C@H]1Cc2cccc(Cl)c2)=O)=O)NCCOc(cccc2)c2/C=C/CNC1=O Chemical compound CC(C)CC(C(NCCCCC(N[C@H]1Cc2cccc(Cl)c2)=O)=O)NCCOc(cccc2)c2/C=C/CNC1=O LSCPFGPGTDVAOJ-IMLLDKLASA-N 0.000 description 1
- ZHFPAKAMFCQYSF-FPVCCHAOSA-N CC(C)NC(C1(CCCC1)NCCOc1c(/C=C/CNC([C@@H](Cc2cc(Cl)ccc2)N)=O)cccc1)=O Chemical compound CC(C)NC(C1(CCCC1)NCCOc1c(/C=C/CNC([C@@H](Cc2cc(Cl)ccc2)N)=O)cccc1)=O ZHFPAKAMFCQYSF-FPVCCHAOSA-N 0.000 description 1
- XGOUIBKZLDCMGX-SUNQPCDNSA-N CC(C)[C@@H](C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1F)C(NCCC1)=O)=O)=O)NC[C@@H](C)Oc2c1cccc2 Chemical compound CC(C)[C@@H](C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1F)C(NCCC1)=O)=O)=O)NC[C@@H](C)Oc2c1cccc2 XGOUIBKZLDCMGX-SUNQPCDNSA-N 0.000 description 1
- FLMZYRKPDRKZHN-DCHXMDBXSA-N CC(CNC(C1CC1)C(N(C)[C@H](C)C(N[C@@H]1Cc(cc2)ccc2Cl)=O)=O)Oc2cc(F)ccc2CCCNC1=O Chemical compound CC(CNC(C1CC1)C(N(C)[C@H](C)C(N[C@@H]1Cc(cc2)ccc2Cl)=O)=O)Oc2cc(F)ccc2CCCNC1=O FLMZYRKPDRKZHN-DCHXMDBXSA-N 0.000 description 1
- PCIYPBHFFTWPAC-RIXNMHOGSA-N CCC(C)[C@@H](C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1Cl)C(NCCC1)=O)=O)=O)NC[C@@H](C)Oc2c1cccc2 Chemical compound CCC(C)[C@@H](C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1Cl)C(NCCC1)=O)=O)=O)NC[C@@H](C)Oc2c1cccc2 PCIYPBHFFTWPAC-RIXNMHOGSA-N 0.000 description 1
- OJESPZZSUUGAKK-RIXNMHOGSA-N CCC(C)[C@@H](C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1F)C(NCCC1)=O)=O)=O)NC[C@@H](C)Oc2c1cccc2 Chemical compound CCC(C)[C@@H](C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1F)C(NCCC1)=O)=O)=O)NC[C@@H](C)Oc2c1cccc2 OJESPZZSUUGAKK-RIXNMHOGSA-N 0.000 description 1
- KJEJZRPHEOIBSD-DVWJTPMSSA-N CCC(C)[C@@H](C(N(C)[C@H](C)C=O)=O)NCCOc1c(CCCNC([C@@H](Cc(cc2)ccc2OC)NC)=O)cccc1 Chemical compound CCC(C)[C@@H](C(N(C)[C@H](C)C=O)=O)NCCOc1c(CCCNC([C@@H](Cc(cc2)ccc2OC)NC)=O)cccc1 KJEJZRPHEOIBSD-DVWJTPMSSA-N 0.000 description 1
- VCORBQCGLWKHPL-YVQHGZASSA-N CCC(C)[C@@H](C(N(C)[C@H](C)COCN[C@H](Cc(cc1)ccc1Cl)C(NCCC1)=O)=O)NCCOC2=C1C=CC(C)C2 Chemical compound CCC(C)[C@@H](C(N(C)[C@H](C)COCN[C@H](Cc(cc1)ccc1Cl)C(NCCC1)=O)=O)NCCOC2=C1C=CC(C)C2 VCORBQCGLWKHPL-YVQHGZASSA-N 0.000 description 1
- SUNUERJCGVNVHY-HFCQSUTLSA-N CCC(C)[C@@H]([C@H](N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1Cl)C(NCCC1)=O)=O)O)NCCOc2c1cccc2 Chemical compound CCC(C)[C@@H]([C@H](N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1Cl)C(NCCC1)=O)=O)O)NCCOc2c1cccc2 SUNUERJCGVNVHY-HFCQSUTLSA-N 0.000 description 1
- QKNFFJHHPCWXTH-GSVOUGTGSA-N C[C@H](C(N)=O)NC Chemical compound C[C@H](C(N)=O)NC QKNFFJHHPCWXTH-GSVOUGTGSA-N 0.000 description 1
- BOEGEFRHBFOWHV-GKCVIINISA-N C[C@H](C(NC/C(/NCCCc1cccc(CC2)c1OC2CN[C@H]1C2CC2)=[O]\C(C2)=C(C)C=CC2F)=O)N(C)C1=O Chemical compound C[C@H](C(NC/C(/NCCCc1cccc(CC2)c1OC2CN[C@H]1C2CC2)=[O]\C(C2)=C(C)C=CC2F)=O)N(C)C1=O BOEGEFRHBFOWHV-GKCVIINISA-N 0.000 description 1
- YJUAKTNWDHAAPJ-JRLVAEJTSA-N C[C@H](C(N[C@H](Cc(cc1)cc(C)c1F)C(NCCCc(ccc(F)c1)c1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O Chemical compound C[C@H](C(N[C@H](Cc(cc1)cc(C)c1F)C(NCCCc(ccc(F)c1)c1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O YJUAKTNWDHAAPJ-JRLVAEJTSA-N 0.000 description 1
- BAYBKNUWBDTZMD-UFKXBGGNSA-N C[C@H](C(N[C@H](Cc(cc1)cc(Cl)c1Cl)C(NCCCc(cccc1)c1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O Chemical compound C[C@H](C(N[C@H](Cc(cc1)cc(Cl)c1Cl)C(NCCCc(cccc1)c1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O BAYBKNUWBDTZMD-UFKXBGGNSA-N 0.000 description 1
- QXKQYGJLFHEJSN-UFKXBGGNSA-N C[C@H](C(N[C@H](Cc(cc1)ccc1Cl)C(NCCCc(ccc(F)c1)c1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O Chemical compound C[C@H](C(N[C@H](Cc(cc1)ccc1Cl)C(NCCCc(ccc(F)c1)c1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O QXKQYGJLFHEJSN-UFKXBGGNSA-N 0.000 description 1
- IIYJZCSRYYWIPD-OXTYCOSGSA-N C[C@H](C(N[C@H](Cc(cc1)ccc1Cl)C(NCCCc1ccccc1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O Chemical compound C[C@H](C(N[C@H](Cc(cc1)ccc1Cl)C(NCCCc1ccccc1OCCN[C@H]1C2CC2)=O)=O)N(C)C1=O IIYJZCSRYYWIPD-OXTYCOSGSA-N 0.000 description 1
- VINZVPGADOTTRZ-STPXHTAQSA-N C[C@H](C(N[C@H](Cc1ccccc1)C(NCCCc1cccc(CC2)c1OC2CN[C@H]1C2CC2)=O)=O)N(C)C1=O Chemical compound C[C@H](C(N[C@H](Cc1ccccc1)C(NCCCc1cccc(CC2)c1OC2CN[C@H]1C2CC2)=O)=O)N(C)C1=O VINZVPGADOTTRZ-STPXHTAQSA-N 0.000 description 1
- RJCWYKKZQVYFIK-ZCFIWIBFSA-N C[C@H](C(OC)=O)Oc(cc(cc1)F)c1Br Chemical compound C[C@H](C(OC)=O)Oc(cc(cc1)F)c1Br RJCWYKKZQVYFIK-ZCFIWIBFSA-N 0.000 description 1
- RDHGCYKVJWBSIQ-LGVUCKNBSA-N C[C@H](C1CC1)NCCOc1ccccc1CCCNC([C@@H](Cc(cc1Cl)ccc1Cl)NC([C@@H](C)N(C)C=O)=O)=O Chemical compound C[C@H](C1CC1)NCCOc1ccccc1CCCNC([C@@H](Cc(cc1Cl)ccc1Cl)NC([C@@H](C)N(C)C=O)=O)=O RDHGCYKVJWBSIQ-LGVUCKNBSA-N 0.000 description 1
- ZXFJLYGLQSJGDT-BXCKHXLXSA-N C[C@H](CN[C@@H](/C(/C)=C/C)C(N(C)[C@H](C)C(N[C@@H]1Cc2ccccc2)=O)=O)Oc2ccccc2CCCNC1=O Chemical compound C[C@H](CN[C@@H](/C(/C)=C/C)C(N(C)[C@H](C)C(N[C@@H]1Cc2ccccc2)=O)=O)Oc2ccccc2CCCNC1=O ZXFJLYGLQSJGDT-BXCKHXLXSA-N 0.000 description 1
- JAQJTCYNCNXEGW-IFGWQFMBSA-N C[C@H](CN[C@@H](C1CC1)C(N(C)[C@H](C)C(N[C@@H]1Cc(cc2)ccc2F)=O)=O)Oc2cc(Cl)ccc2CCCNC1=O Chemical compound C[C@H](CN[C@@H](C1CC1)C(N(C)[C@H](C)C(N[C@@H]1Cc(cc2)ccc2F)=O)=O)Oc2cc(Cl)ccc2CCCNC1=O JAQJTCYNCNXEGW-IFGWQFMBSA-N 0.000 description 1
- IEAUXEJFKGIBRN-IFGWQFMBSA-N C[C@H](CN[C@@H](C1CC1)C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1F)C(NCCC1)=O)=O)=O)Oc2c1ccc(F)c2 Chemical compound C[C@H](CN[C@@H](C1CC1)C(N(C)[C@H](C)C(N[C@H](Cc(cc1)ccc1F)C(NCCC1)=O)=O)=O)Oc2c1ccc(F)c2 IEAUXEJFKGIBRN-IFGWQFMBSA-N 0.000 description 1
- MVOYCXFKHYEJJR-SOLZYKTISA-N C[C@H](CN[C@H](C)C1CC1)Oc1c(CCCNC([C@@H](Cc(cc2)ccc2F)NC([C@@H](C)N(C)C=O)=O)=O)ccc(F)c1 Chemical compound C[C@H](CN[C@H](C)C1CC1)Oc1c(CCCNC([C@@H](Cc(cc2)ccc2F)NC([C@@H](C)N(C)C=O)=O)=O)ccc(F)c1 MVOYCXFKHYEJJR-SOLZYKTISA-N 0.000 description 1
- FHZPSAWKIYTAMV-ZCFIWIBFSA-N C[C@H](CO)Oc(cc(cc1)F)c1Br Chemical compound C[C@H](CO)Oc(cc(cc1)F)c1Br FHZPSAWKIYTAMV-ZCFIWIBFSA-N 0.000 description 1
- FWYMXRDSKWSAKP-LVPRMVSMSA-N C[C@H](COCN[C@H](Cc(cc1)ccc1F)C(NCCCc(ccc(F)c1)c1OCCN[C@H]1C2CC2)=O)N(C)C1=O Chemical compound C[C@H](COCN[C@H](Cc(cc1)ccc1F)C(NCCCc(ccc(F)c1)c1OCCN[C@H]1C2CC2)=O)N(C)C1=O FWYMXRDSKWSAKP-LVPRMVSMSA-N 0.000 description 1
- KCTXWSAAZFMQSM-MFJULSPGSA-N Nc1cccc(C[C@H](C(NC/C=C/c2ccccc2OCCNC2(CCCC2)C(NC2)=O)=O)NC2=O)c1 Chemical compound Nc1cccc(C[C@H](C(NC/C=C/c2ccccc2OCCNC2(CCCC2)C(NC2)=O)=O)NC2=O)c1 KCTXWSAAZFMQSM-MFJULSPGSA-N 0.000 description 1
- YZIXMEXARCDRCW-UHFFFAOYSA-N OCCCc1c(C=O)cccc1 Chemical compound OCCCc1c(C=O)cccc1 YZIXMEXARCDRCW-UHFFFAOYSA-N 0.000 description 1
- VCSQSPVHFDOWER-UHFFFAOYSA-N OCCCc1ccccc1CO Chemical compound OCCCc1ccccc1CO VCSQSPVHFDOWER-UHFFFAOYSA-N 0.000 description 1
- HUVAOAVBKOVPBZ-UHFFFAOYSA-N Oc(cc(cc1)F)c1Br Chemical compound Oc(cc(cc1)F)c1Br HUVAOAVBKOVPBZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/872,142 | 2004-06-18 | ||
US10/872,142 US7521420B2 (en) | 2003-06-18 | 2004-06-18 | Macrocyclic antagonists of the motilin receptor |
US62164204P | 2004-10-26 | 2004-10-26 | |
US60/621,642 | 2004-10-26 | ||
US62200504P | 2004-10-27 | 2004-10-27 | |
US60/622,055 | 2004-10-27 | ||
US60/622,005 | 2004-10-27 | ||
US64227105P | 2005-01-07 | 2005-01-07 | |
US60/642,271 | 2005-01-07 | ||
US11/149,731 US7476653B2 (en) | 2003-06-18 | 2005-06-10 | Macrocyclic modulators of the ghrelin receptor |
US11/149,731 | 2005-06-10 | ||
PCT/US2005/020857 WO2006009674A1 (en) | 2004-06-18 | 2005-06-13 | Macrocyclic modulators of the ghrelin receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101111512A CN101111512A (zh) | 2008-01-23 |
CN101111512B true CN101111512B (zh) | 2013-05-01 |
Family
ID=35427667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800280726A Expired - Fee Related CN101111512B (zh) | 2004-06-18 | 2005-06-13 | 生长素释放肽受体的大环调节剂 |
Country Status (7)
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090198050A1 (en) * | 2003-06-18 | 2009-08-06 | Tranzyme Pharma Inc. | Macrocyclic Modulators of the Ghrelin Receptor |
US8921521B2 (en) | 2003-06-18 | 2014-12-30 | Ocera Therapeutics, Inc. | Macrocyclic modulators of the Ghrelin receptor |
US7491695B2 (en) * | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
EP1633774B1 (en) * | 2003-06-18 | 2010-02-17 | Tranzyme Pharma Inc. | Macrocyclic antagonists of the motilin receptor |
US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
WO2005012332A1 (en) * | 2003-07-31 | 2005-02-10 | Tranzyme Pharma | Spatially-defined macrocycles incorporating peptide bond surrogates |
EP2316846B1 (en) * | 2003-07-31 | 2019-10-02 | Ocera Therapeutics, Inc. | Spatially-defined macrocyclic compounds useful for drug discovery |
JP5730835B2 (ja) * | 2004-06-18 | 2015-06-10 | オセラ セラピューティクス, インコーポレイテッド | グレリン受容体の大環状モジュレーターの使用方法 |
JP5739766B2 (ja) * | 2004-06-18 | 2015-06-24 | オセラ セラピューティクス, インコーポレイテッド | グレリン受容体の大環状モジュレーターの使用方法 |
WO2006137974A2 (en) * | 2005-06-13 | 2006-12-28 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
US20090275648A1 (en) * | 2005-06-13 | 2009-11-05 | Fraser Graeme L | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
SI1937262T1 (sl) * | 2005-09-29 | 2019-09-30 | Ipsen Pharma | Spojina za uporabo pri zdravljenju gastrointestinalne dismotilitete |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
WO2007106385A2 (en) * | 2006-03-10 | 2007-09-20 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment |
US8088733B2 (en) * | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
WO2008033328A2 (en) | 2006-09-11 | 2008-03-20 | Tranzyme Pharma, Inc. | Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders |
PT2118123E (pt) | 2007-01-31 | 2016-02-10 | Harvard College | Péptidos de p53 estabilizados e suas utilizações |
EP2644618B1 (en) | 2007-02-09 | 2016-08-17 | Ocera Therapeutics, Inc. | tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators |
EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
US20100216706A1 (en) * | 2007-05-15 | 2010-08-26 | Horvath Tamas L | Ghrelin Protects Substantia Nigra Dopamine Neurons |
JP2011507842A (ja) * | 2007-12-21 | 2011-03-10 | ヘルシン・セラピューティクス・ユーエス・インコーポレイテッド | 消化器系の運動をイパモレリンを用いて刺激する方法 |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US9724381B2 (en) | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
EP2483407A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
BR112012007183A2 (pt) * | 2009-09-30 | 2017-06-20 | Tranzyme Pharma Inc | solvato de um sal de um composto macrocíclico, forma polimórfica, processos para preparar a forma polimórfica e uma composição farmacêutica, composição farmacêutica, sal de um composto macrocíclico, e, métodos para estimular motilidade gastrintestinal, para tratar um distúrbio gastrintestinal e para tratar um indivíduo, e, kit |
US20120270807A1 (en) * | 2009-10-23 | 2012-10-25 | Marsault Eric | Macrocyclic inhibitors of serine protease enzymes |
US20110105389A1 (en) | 2009-10-30 | 2011-05-05 | Hoveyda Hamid R | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same |
AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
US8835444B2 (en) | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
WO2011146845A1 (en) * | 2010-05-21 | 2011-11-24 | Tranzyme Pharma, Inc. | Modified macrocyclic ghrelin receptor modulators and methods of using the same |
US9315546B2 (en) | 2010-06-16 | 2016-04-19 | The Administrators Of The Tulane Educational Fund | Growth hormone secretatogue receptor antagonists and uses thereof |
US8975232B2 (en) | 2010-07-29 | 2015-03-10 | President And Fellows Of Harvard College | Macrocyclic kinase inhibitors and uses thereof |
CA2807685C (en) | 2010-08-13 | 2020-10-06 | Aileron Therapeutics, Inc. | P53 derived peptidomimetic macrocycle |
AU2012279202A1 (en) | 2011-07-01 | 2014-02-20 | President And Fellows Of Harvard College | Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof |
TWI643868B (zh) | 2011-10-18 | 2018-12-11 | 艾利倫治療公司 | 擬肽巨環化合物 |
CN102557989B (zh) * | 2011-12-19 | 2013-12-25 | 深圳翰宇药业股份有限公司 | 优利莫瑞林中间体以及优利莫瑞林制备方法 |
US10039813B2 (en) | 2012-02-07 | 2018-08-07 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
MX362492B (es) | 2012-02-15 | 2019-01-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos. |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
MX2015003564A (es) * | 2012-09-27 | 2015-11-16 | Aratana Therapeutics Inc | Composiciones y metodos de uso de un compuesto de control de inapetencia. |
WO2014065341A1 (ja) | 2012-10-24 | 2014-05-01 | 第一三共株式会社 | 筋萎縮性側索硬化症治療剤 |
EP2914256B1 (en) | 2012-11-01 | 2019-07-31 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
CN103864588B (zh) * | 2014-03-25 | 2015-09-09 | 河北工业大学 | 一种2,3-二甲氧基苯甲醛的制备方法 |
SG10201902594QA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
EA201791038A1 (ru) | 2014-11-12 | 2017-11-30 | Лирик Фармасьютикалз Инк. | Лечение непереносимости энтерального питания |
PL3250203T3 (pl) | 2015-01-28 | 2022-04-25 | Elanco Animal Health Incorporated | Kompozycja do przewlekłego stosowania jako środek wspomagający przybieranie na wadze |
US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
AU2016235424A1 (en) | 2015-03-20 | 2017-10-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
US11040976B2 (en) | 2015-04-24 | 2021-06-22 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof |
ES2811911T3 (es) | 2015-10-27 | 2021-03-15 | Hoffmann La Roche | Macrociclos peptídicos frente a Acinetobacter baumannii |
WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
EP3388444A1 (en) | 2017-04-10 | 2018-10-17 | F. Hoffmann-La Roche AG | Anti-bacterial peptide macrocycles and use thereof |
CN107759660A (zh) * | 2017-12-05 | 2018-03-06 | 陕西慧康生物科技有限责任公司 | 一种三肽‑29的液‑固相合成方法 |
US11674136B2 (en) | 2018-02-09 | 2023-06-13 | President And Fellows Of Harvard College | DNA-templated macrocycle library |
US11505573B2 (en) | 2018-03-28 | 2022-11-22 | Hoffmann-La Roche Inc. | Peptide macrocycles against Acinetobacter baumannii |
US11819532B2 (en) | 2018-04-23 | 2023-11-21 | Hoffmann-La Roche Inc. | Peptide macrocycles against Acinetobacter baumannii |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1301160A (zh) * | 1998-06-16 | 2001-06-27 | 辉瑞产品公司 | 用于治疗肌与骨骼脆弱的(选择性)雌激素受体调节剂(serm)和生长激素促分泌剂(ghs)的治疗用联合形式 |
CN1316908A (zh) * | 1998-09-03 | 2001-10-10 | 诺兰兹公司 | 神经保护 |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
NZ188418A (en) | 1977-10-03 | 1981-02-11 | Mobil Oil Corp | Lubricants containing oil and an oxazoline |
AU628322B2 (en) | 1988-01-28 | 1992-09-17 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
JPH03502329A (ja) | 1988-01-28 | 1991-05-30 | ポリゲン ホールディング コーポレイション | 成長ホルモン放出活性を有するポリペプチド化合物類 |
EP0554381B2 (en) | 1990-10-25 | 2000-04-26 | Genentech, Inc. | Use of protective agents against reactive oxygen species |
US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
AU676525B2 (en) | 1992-11-06 | 1997-03-13 | Merck & Co., Inc. | Substituted dipeptide analogs promote release of growth hormone |
US5726319A (en) | 1992-11-06 | 1998-03-10 | Merck & Co., Inc. | Biphenyl substituted dipeptide analogs promote release of growth hormone |
WO1994013696A1 (en) | 1992-12-11 | 1994-06-23 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
US5536716A (en) | 1992-12-11 | 1996-07-16 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
BR9407869A (pt) | 1993-10-19 | 1996-10-29 | Merck & Co Inc | Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose |
US5494919A (en) | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
JPH10506091A (ja) | 1993-11-09 | 1998-06-16 | メルク エンド カンパニー インコーポレーテッド | 成長ホルモン放出促進性のピペリジン、ピロリジンおよびヘキサヒドロ−1h−アゼピン類 |
US5492916A (en) | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
AU684878B2 (en) | 1993-11-24 | 1998-01-08 | Merck & Co., Inc. | Compounds and the use thereof to promote the release of growth hormone(s) |
US5721251A (en) | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
ATE197158T1 (de) | 1993-12-23 | 2000-11-15 | Novo Nordisk As | Verbindungen mit wachstumshormonfreisetzenden eigenschaften |
RU2167881C2 (ru) | 1993-12-23 | 2001-05-27 | Ново Нордиск А/С | Соединения, способствующие высвобождению гормона роста |
US5721250A (en) | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
WO1995034311A1 (en) | 1994-06-13 | 1995-12-21 | Merck & Co., Inc. | Piperazine compounds promote release of growth hormone |
AU3128195A (en) | 1994-07-20 | 1996-02-16 | Merck & Co., Inc. | Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone |
US5798337A (en) | 1994-11-16 | 1998-08-25 | Genentech, Inc. | Low molecular weight peptidomimetic growth hormone secretagogues |
AU4495996A (en) | 1995-01-25 | 1996-08-14 | Nippon Chemiphar Co. Ltd. | Dihydrophenazine derivatives |
CZ238197A3 (en) | 1995-01-27 | 1997-12-17 | Novo Nordisk As | Growth hormone formation stimulating compounds |
WO1996024587A1 (en) | 1995-02-09 | 1996-08-15 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
WO1996024580A1 (en) | 1995-02-09 | 1996-08-15 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US5559128A (en) | 1995-04-18 | 1996-09-24 | Merck & Co., Inc. | 3-substituted piperidines promote release of growth hormone |
AU5486396A (en) | 1995-04-19 | 1996-11-07 | Merck & Co., Inc. | Process for the preparation of spiroindolines |
WO1996035713A1 (en) | 1995-05-08 | 1996-11-14 | Pfizer, Inc. | Dipeptides which promote release of growth hormone |
ES2235171T3 (es) | 1995-05-29 | 2005-07-01 | Pfizer Inc. | Dipeptidos que promueven la liberacion de la hormona de crecimiento. |
AU711104B2 (en) | 1995-06-22 | 1999-10-07 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
CA2203424A1 (en) | 1995-08-21 | 1997-02-27 | Eli Lilly And Company | 2-acylaminopropanamines as growth hormone secretagogues |
EP0761220A1 (en) | 1995-08-21 | 1997-03-12 | Eli Lilly And Company | 2-Acylaminopropanamides as growth hormone secretagogues |
EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
WO1997011697A1 (en) | 1995-09-26 | 1997-04-03 | Merck & Co., Inc. | 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone |
AU7522896A (en) | 1995-10-27 | 1997-05-15 | Merck & Co., Inc. | Wet granulation formulation of a growth hormone secretagogue |
EA199800337A1 (ru) | 1995-10-27 | 1998-10-29 | Мерк Энд Ко., Инк. | Способ получения гормона роста, усиливающего секрецию |
US5767124A (en) | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
AU7468596A (en) | 1995-10-27 | 1997-05-15 | Merck & Co., Inc. | Process for the preparation of a growth hormone secretagogue |
WO1997022004A1 (en) | 1995-12-13 | 1997-06-19 | Merck & Co., Inc. | Assays for growth hormone secretagogue receptors |
JP3754084B2 (ja) | 1995-12-13 | 2006-03-08 | メルク エンド カンパニー インコーポレーテッド | 成長ホルモン分泌促進薬受容体ファミリー |
WO1997022367A1 (en) | 1995-12-20 | 1997-06-26 | Merck & Co., Inc. | Radiolabeled growth hormone secretagogue |
IT1277113B1 (it) | 1995-12-20 | 1997-11-04 | Romano Deghenghi | Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita |
JP3701686B2 (ja) | 1995-12-22 | 2005-10-05 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン放出特性を有する化合物 |
TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
AU2334097A (en) | 1996-03-21 | 1997-10-10 | Merck & Co., Inc. | 4-spiroindoline piperidines promote release of growth hormone |
WO1997036873A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
SE9601397D0 (sv) | 1996-04-12 | 1996-04-12 | Pharmacia Ab | Use of growth hormone |
EP0910579A1 (en) | 1996-04-19 | 1999-04-28 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US5919777A (en) | 1996-04-24 | 1999-07-06 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
AU722421B2 (en) | 1996-04-24 | 2000-08-03 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
WO1997041878A1 (en) | 1996-05-07 | 1997-11-13 | Merck & Co., Inc. | Treatment of mood disorders with a growth hormone secretagogue |
JP2000511885A (ja) | 1996-05-07 | 2000-09-12 | メルク エンド カンパニー インコーポレーテッド | 成長ホルモン分泌促進薬による睡眠の強化 |
EP0912551A1 (en) | 1996-05-14 | 1999-05-06 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
US6071926A (en) | 1996-05-22 | 2000-06-06 | Arch Development Corporation | Sleep quality improvement using a growth hormone secretagogue |
BR9709499A (pt) | 1996-05-31 | 1999-08-10 | Novo Nordisk As | Processo para prevenção ou tratamento de osteoporose e de perturbações relacionamas uso de um componente de hormónio do crescimento uso de uma composição com uma ação de anti-reabsorção sobre os ossos e produtos |
ATE304528T1 (de) | 1996-07-22 | 2005-09-15 | Novo Nordisk As | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
AU4342097A (en) | 1996-09-13 | 1998-04-02 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
AU4993497A (en) | 1996-10-25 | 1998-05-22 | Merck & Co., Inc. | Convergent process for the preparation of a growth hormone secretagogue |
SE9703929D0 (sv) | 1996-11-22 | 1997-10-28 | Pharmacia & Upjohn Ab | Therapeutical use and method |
AU6747498A (en) | 1997-04-11 | 1998-11-11 | Sumitomo Pharmaceuticals Company, Limited | Benzene derivatives |
JP2000514838A (ja) | 1997-05-14 | 2000-11-07 | 藤沢薬品工業株式会社 | 成長ホルモンの放出を促進するピペリジノ誘導体 |
JP4116097B2 (ja) | 1997-06-20 | 2008-07-09 | ノボ ノルディスク アクティーゼルスカブ | 成長ホルモン放出特性をもつ化合物 |
UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
ATE356139T1 (de) | 1997-06-25 | 2007-03-15 | Pfizer | Dipeptidderivate zur förderung der sekretion von wachstumshormon |
ZA987383B (en) | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
US6864250B1 (en) | 1997-08-22 | 2005-03-08 | Kaken Pharmaceutical Co., Ltd. | N-acylated lipophilic amino acid derivatives |
WO1999012969A1 (en) | 1997-09-08 | 1999-03-18 | Metabolic Pharmaceuticals Ltd. | Treatment of obesity |
ATE470671T1 (de) | 1998-01-16 | 2010-06-15 | Helsinn Therapeutics Us Inc | Verbindungen mit wachstumshormon-freisetzender eigenschaft |
WO1999039730A1 (fr) | 1998-02-09 | 1999-08-12 | Kaken Pharmaceutical Co., Ltd. | Preparation a administration orale contenant des peptides favorisant la secretion d'hormone de croissance |
ATE254632T1 (de) | 1998-03-03 | 2003-12-15 | Novo Nordisk As | Neue salzformn von (2e)-5-amino-5-methylhex-2- enolsäure n-methyl-n-((1r)-1-(methylcarbamoyl)-2- phruylrthyl) carbamoyl)-2-(2-naphtyl)ethyl)amid |
MA26618A1 (fr) * | 1998-04-09 | 2004-12-20 | Smithkline Beecham Corp | Composes et compositions pharmaceutiques pour le traitement du paludisme |
RU2243215C2 (ru) | 1998-05-11 | 2004-12-27 | Ново Нордиск А/С | Производные пиперидинкарбоновых кислот, фармацевтические композиции, содержащие их, способ стимуляции секреции гормона роста |
JP4574849B2 (ja) | 1998-06-09 | 2010-11-04 | サファイア セラピューティクス,インコーポレイティド | 成長ホルモン放出特性を有する化合物を調製するための方法 |
SK18902000A3 (sk) | 1998-06-16 | 2001-12-03 | Pfizer Products Inc. | Terapeutické kombinácie (selektívnych) modulátorov estrogénneho receptora (serm) a prostriedkov podporujúcich sekréciu rastového hormónu (ghs) na liečbu muskuloskeletárnej fragility |
DE69943239D1 (de) | 1998-06-30 | 2011-04-14 | Novo Nordisk As | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
DE19831217A1 (de) * | 1998-07-03 | 2000-01-05 | Schering Ag | Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik |
US6645726B1 (en) | 1998-08-10 | 2003-11-11 | Merck & Co., Inc. | Canine growth hormone secretagogue receptor |
EP1105376B1 (en) | 1998-08-20 | 2005-02-09 | Sumitomo Pharmaceuticals Company, Limited | Oxindole derivatives as growth hormone releasers |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
WO2001000830A1 (en) | 1999-06-30 | 2001-01-04 | Zymogenetics, Inc. | Sgip peptides |
CA2284459C (en) * | 1999-10-04 | 2012-12-11 | Neokimia Inc. | Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery |
EP1258250B1 (en) | 1999-12-28 | 2005-09-14 | Kaken Pharmaceutical Co., Ltd. | Nerve protective drugs |
MXPA02010375A (es) * | 2000-04-19 | 2003-04-25 | Schering Corp | Inhibidores macrociclicos de la ns3-serina proteasa del virus de la hepatitis c que comprenden porciones alquil y arilalanina p2. |
CA2411667A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co. Inc. | Ghrelin analogs |
ES2333097T3 (es) * | 2000-05-31 | 2010-02-17 | Raqualia Pharma Inc | Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal. |
IL153067A0 (en) | 2000-06-13 | 2003-06-24 | Zentaris Ag | Growth hormone secretagogues |
CA2413252A1 (en) | 2000-06-23 | 2002-12-20 | Takahiko Murata | Preventives or remedies for heart failure |
US6576686B1 (en) | 2000-06-27 | 2003-06-10 | Exxonmobil Chemical Patents Inc. | Road marking compound comprising linear tetrablock copolymers |
US6635784B2 (en) * | 2000-09-29 | 2003-10-21 | Eastman Chemical Company | Process for the preparation of enantiomerically-enriched cyclopropylalanine derivates |
US20020168343A1 (en) | 2001-02-14 | 2002-11-14 | Curiel David T. | Combined transductional and transcriptional targeting system for improved gene delivery |
ITMI20011445A1 (it) | 2001-07-06 | 2003-01-06 | Europ Geie | Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita |
JPWO2004014412A1 (ja) | 2002-08-09 | 2005-12-02 | 科研製薬株式会社 | 心筋細胞保護剤 |
EP1633774B1 (en) | 2003-06-18 | 2010-02-17 | Tranzyme Pharma Inc. | Macrocyclic antagonists of the motilin receptor |
US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
US7491695B2 (en) | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
WO2005012332A1 (en) | 2003-07-31 | 2005-02-10 | Tranzyme Pharma | Spatially-defined macrocycles incorporating peptide bond surrogates |
EP2316846B1 (en) * | 2003-07-31 | 2019-10-02 | Ocera Therapeutics, Inc. | Spatially-defined macrocyclic compounds useful for drug discovery |
EP2644618B1 (en) * | 2007-02-09 | 2016-08-17 | Ocera Therapeutics, Inc. | tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators |
BR112012007183A2 (pt) | 2009-09-30 | 2017-06-20 | Tranzyme Pharma Inc | solvato de um sal de um composto macrocíclico, forma polimórfica, processos para preparar a forma polimórfica e uma composição farmacêutica, composição farmacêutica, sal de um composto macrocíclico, e, métodos para estimular motilidade gastrintestinal, para tratar um distúrbio gastrintestinal e para tratar um indivíduo, e, kit |
-
2005
- 2005-06-10 US US11/149,731 patent/US7476653B2/en not_active Ceased
- 2005-06-13 JP JP2007516620A patent/JP5363726B2/ja not_active Expired - Fee Related
- 2005-06-13 EP EP11009051A patent/EP2457925A1/en not_active Withdrawn
- 2005-06-13 ES ES05785185T patent/ES2393498T3/es active Active
- 2005-06-13 CA CA2579726A patent/CA2579726C/en not_active Expired - Fee Related
- 2005-06-13 CN CN2005800280726A patent/CN101111512B/zh not_active Expired - Fee Related
- 2005-06-13 WO PCT/US2005/020857 patent/WO2006009674A1/en active Application Filing
- 2005-06-13 EP EP05785185A patent/EP1773869B9/en not_active Not-in-force
- 2005-06-13 EP EP11009050.3A patent/EP2457893B1/en active Active
-
2009
- 2009-01-09 US US12/351,395 patent/US8334256B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1301160A (zh) * | 1998-06-16 | 2001-06-27 | 辉瑞产品公司 | 用于治疗肌与骨骼脆弱的(选择性)雌激素受体调节剂(serm)和生长激素促分泌剂(ghs)的治疗用联合形式 |
CN1316908A (zh) * | 1998-09-03 | 2001-10-10 | 诺兰兹公司 | 神经保护 |
Also Published As
Publication number | Publication date |
---|---|
JP2008504238A (ja) | 2008-02-14 |
EP1773869B1 (en) | 2012-08-22 |
WO2006009674A8 (en) | 2009-11-26 |
ES2393498T3 (es) | 2012-12-21 |
WO2006009674A1 (en) | 2006-01-26 |
EP1773869A1 (en) | 2007-04-18 |
US8334256B2 (en) | 2012-12-18 |
EP2457925A1 (en) | 2012-05-30 |
US20060025566A1 (en) | 2006-02-02 |
US20090221689A1 (en) | 2009-09-03 |
CN101111512A (zh) | 2008-01-23 |
CA2579726C (en) | 2015-01-13 |
EP1773869B9 (en) | 2013-01-23 |
CA2579726A1 (en) | 2006-01-26 |
JP5363726B2 (ja) | 2013-12-11 |
EP2457893A1 (en) | 2012-05-30 |
US7476653B2 (en) | 2009-01-13 |
EP2457893B1 (en) | 2017-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101111512B (zh) | 生长素释放肽受体的大环调节剂 | |
JP5219509B2 (ja) | グレリン受容体の大環状モジュレーターの使用方法 | |
CN101657436A (zh) | 大环生长素释放肽受体调节剂及其使用方法 | |
USRE42013E1 (en) | Macrocyclic modulators of the ghrelin receptor | |
USRE42624E1 (en) | Methods of using macrocyclic modulators of the ghrelin receptor | |
US20090198050A1 (en) | Macrocyclic Modulators of the Ghrelin Receptor | |
CA2583345A1 (en) | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same | |
WO2006046977A1 (en) | Macrocyclic ghrelin receptor antagonists and methods of using the same | |
US9493505B2 (en) | Macrocyclic modulators of the ghrelin receptor | |
US20180110824A1 (en) | Macrocyclic Modulators of the Ghrelin Receptor | |
JP5730835B2 (ja) | グレリン受容体の大環状モジュレーターの使用方法 | |
JP5739766B2 (ja) | グレリン受容体の大環状モジュレーターの使用方法 | |
ES2646887T3 (es) | Compuestos intermedios para moduladores macrocíclicos del receptor de ghrelina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: OCERA THERAPEUTICS INC. Free format text: FORMER OWNER: TRANZYME PHARMA INC. Effective date: 20140516 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140516 Address after: American California Patentee after: Ocera Therapeutics Inc. Address before: North Carolina Patentee before: Tranzyme Pharma Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130501 Termination date: 20200613 |